Samra Turajlic discusses the contribution of small insertions and deletions to tumour-specific antigen analyses.
Ricky Sharma discusses results from three prospective trials on the use of selective internal radiotherapy for liver metastases from colorectal cancer.
Percy Lee discusses the impact of prior radiotherapy on the efficacy of pembrolizumab when used to treat non-small cell lung cancer.
Martin Taphoorn outlines the importance of palliative care for patients with gliomas.
Sandro Porceddu discusses the new Lancet Oncology Series on head and neck cancer.
Michele Cavo discusses the International Myeloma Working Group’s recommendations on the use of 18F-FDG PET/CT for patients with multiple myeloma and other plasma cell dyscrasias.
Lesley Seymour discusses the iRECIST guidelines for assessing tumour responses in immunotherapy trials.
Javier Torres-Roca and Louis Harrison join us to discuss their work on genome modelling and its uses in calculating the appropriate radiation dosage.
Ann Partridge talks about cancer survival in the USA.
Rafael Rossell discusses RET inhibitors and non-small cell lung cancer.
Brigitta Baumert discusses her article on quality of life in patients with high-risk, low-grade glioma.
Brian Rini discusses active surveillance for patients with metastatic renal cell carcinoma.
Shaji Kumar discusses updated consensus criteria from the International Myeloma Working Group for response and minimal residual disease assessment in multiple myeloma.
Catherine Sauvaget and Ryo Konno discuss Japan’s low uptake of screening programmes for breast and cervical cancer.
Anish Thomas discusses use of antibody-drug conjugates for cancer therapy.
Jean-Claude Dupont and François Doz discuss ethical issues in paediatric oncology clinical trials.
Michael Taylor discusses treatment approaches to the rare brain tumour that generally affects children, medulloblastoma.
Sibylle Loibl discusses the findings and clinical implications of the GeparSepto trial.
Dr. Richard Carvajal discusses aspects of treatment and research for rare cancers.
Discussion of two new treatment approaches to indolent lymphoma and mantle-cell lymphoma, haematological diseases with generally poor response to chemotherapy.
© 2009-2013 Ebling Library, UW-Madison
750 Highland Ave, Madison, WI, 53705-2221